| Floyd Steven White, | |
|
3700 E Main St, Blytheville, AR 72315-6881 | |
| (870) 763-1013 | |
| Not Available |
| Full Name | Floyd Steven White |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 3700 E Main St, Blytheville, Arkansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245831593 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | PD07171 (Arkansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Floyd Steven White, 3700 E Main St, Blytheville, AR 72315-6881 Ph: (870) 763-1013 | Floyd Steven White, 3700 E Main St, Blytheville, AR 72315-6881 Ph: (870) 763-1013 |
News Archive
Pacific Islanders are persons who trace their roots to the native peoples of Hawaii, Guam, Samoa, or other Pacific Islands. Although they make up the third fastest growing racial group in the U.S., their mental health needs and attitudes regarding mental illness are poorly understood.
Whether a women gets pregnant the "traditional" way or by assisted reproduction has no effect on the birthing process itself or the baby, researchers at the Norwegian University of Science and Technology (NTNU) have found.
For the first time to date, research published in the October edition of the Journal of Thoracic Oncology (JTO) sought to determine the use of chemotherapy in a contemporary, diverse non-small cell lung cancer (NSCLC) population encompassing all patient ages. Prior population-based studies have shown that only 20 to 30 percent of advanced lung cancer patients receive chemotherapy treatment.
Genzyme, a Sanofi company, reports today that the Phase lll CARE-MS ll trial met both of its co-primary endpoints. Relapse rate and sustained accumulation (worsening) of disability (SAD) were significantly reduced in multiple sclerosis patients receiving alemtuzumab as compared with Rebif.
YM BioSciences Inc., announced that the FDA has advised the Company that it may now enroll patients at US clinical sites into two ongoing randomized, double-blind Phase II trials of its lead product, nimotuzumab. One of the two trials is in non-small-cell lung cancer (NSCLC) patients who are ineligible for curative treatment and being treated palliatively and the other in patients with brain metastases from NSCLC. Current NSCLC palliative treatment and treatment for brain metastases is radiation alone.
› Verified 4 days ago
Stanley Wilson Crisler, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3700 E State Highway 18, Blytheville, AR 72315 Phone: 870-763-1013 Fax: 870-763-4963 | |
Dr. Cherri Muldrew, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 400 W Moultrie Dr, Blytheville, AR 72315 Phone: 870-763-7951 Fax: 870-763-7958 | |
Coty Prentice Martin, DOCTOR OF PHARMACY Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 400 W Moultrie Dr, Blytheville, AR 72315 Phone: 870-763-7951 Fax: 870-763-7958 | |
Dr. Robert Austin Blue, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 400 W Moultrie Dr, Blytheville, AR 72315 Phone: 870-763-7951 | |
Danesha Williams, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 400 W Moultrie Dr, Blytheville, AR 72315 Phone: 870-763-7958 Fax: 870-763-7958 | |
Dr. Edwin K Muldrew, PHARM.D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3700 E Hwy 18, Blytheville, AR 72315 Phone: 870-763-1013 |